Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) Operating Expenses (2020 - 2026)

Opus Genetics has reported Operating Expenses over the past 12 years, most recently at $16.5 million for Q1 2026.

  • Quarterly Operating Expenses rose 15.54% to $16.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $55.0 million through Mar 2026, down 29.42% year-over-year, with the annual reading at $52.8 million for FY2025, 27.74% down from the prior year.
  • Operating Expenses was $16.5 million for Q1 2026 at Opus Genetics, up from $15.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $42.3 million in Q4 2024 and troughed at $4.5 million in Q3 2022.
  • The 5-year median for Operating Expenses is $9.4 million (2024), against an average of $11.4 million.
  • Year-over-year, Operating Expenses soared 494.54% in 2024 and then plummeted 63.81% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $5.6 million in 2022, then rose by 26.24% to $7.1 million in 2023, then soared by 494.54% to $42.3 million in 2024, then crashed by 63.81% to $15.3 million in 2025, then grew by 7.85% to $16.5 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Operating Expenses are $16.5 million (Q1 2026), $15.3 million (Q4 2025), and $11.4 million (Q3 2025).